Mumbai-based Lupin has completed its acquisition of privately-held GAVIS Pharmaceuticals and Novel Laboratories (GAVIS).
New Jersey-based GAVIS brings with the sale its U.S.-based manufacturing and research organisation. The NJ manufacturing facility is Lupin's first manufacturing site in the United States.
The acquisition, which will broaden Lupin's pipeline in dermatology, controlled substance products and niche generic, also adds GAVIS' 62 abbreviated new drug applications (ANDAs) filings pending approval with the U.S. FDA and a pipeline of over 65 products under development.
Read the IBT article